Top Singapore Biotech Companies (41)
ProfilePrint is an A.I.-driven predictive and prescriptive profiler, providing users with accessible, affordable, and portable solutions to ascertain and predict quality and profile of a food ingredient at the point of use, within seconds. Today, an enormous amount of resources are required to physically grade food samples across multiple stages of the global supply chain. ProfilePrint’s solution redefines transaction standards, and offers sellers and buyers an unbiased reference point, expediting existing quality assessment processes – from the farm all the way to end-buyers. Our headquarter is in Singapore with sales offices in Belgium, Japan and China. Founded in 2017, ProfilePrint is funded by international venture funds, Singapore government and strategic investors including Cargill, Louis Dreyfus, Olam, Sucafina and Sinar Mas. Our solution is deployed in over 26 cities globally across five continents (North America, Latin America, Africa, Europe and Asia).
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, Agilent provides laboratory solutions to meet their full spectrum of needs. We work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. Our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. Customers trust Agilent for solutions that enable insights...for a better world.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
Esco Lifesciences is a world-leading manufacturer and service provider of life science tools. Esco contributes to meeting the challenges of the 21st century with a diverse range of business units—Scientific, Medical, Healthcare, and Aster. The company continuously innovates its products to help clinical and industrial laboratories conduct successful research and development, quality control, and analysis. Esco continues to provide reliable world-class equipment to help pharmaceutical companies make safer and more cost-effective products. And with the increasing demand of the IVF industry, the company has developed efficient ART equipment to enable equitable access to infertility care. With its global headquarters in Singapore, Esco has an extensive sales network that spans more than 100 countries, direct sales and service offices in over 21 countries, 8 manufacturing and R&D centers in the US, Europe, the UK, China, and Singapore, and more than 1500 employees globally.
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, our experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. See our Community Guidelines: bit.ly/smcgl See our Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Curiox Biosystems is committed to enabling accurate biological analysis through automation. Next-generation methods and applications--including single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy--deserve a next-generation approach to preparing samples for analysis. That’s why Curiox invented Laminar Wash technology, the only sample preparation method that eliminates centrifugation and the problems it introduces. The methodology keeps cells in their native state, improves cell retention and viability, and enhances reproducibility and miniaturization, ultimately leading to reduced costs and workflow standardization.
Systemic Bio is a 3D Systems company based in Houston, Texas, focused on the development of vascularized organ models made out of hydrogels and human cells to be used for drug discovery and development.
At KROSSLINKER, we innovate and transform Aerogel for challenging insulation applications. Our first product aims to serve the cold-chain biopharma packaging industry by protecting temperature-sensitive pharmaceuticals, precious biologics, and vaccines throughout their shipping journey with our transformative technology.
X-ZELL is an award-winning medical technology start-up specialising in next-generation cytology. Cytology – or cytopathology – is the science of diagnosing diseases by examining single atypical cells or cell clusters. X-ZELL has developed a plug-and-play solution for the detection, visualization and digitization of these phenomena in minimally invasive body liquids. Slotting seamlessly into clinical routine, it does not require complex specimen preparation and reduces the average time from sample to diagnosis from 48h to less than 4h. The result: better diagnostics and improved patient care. X-ZELL is headquartered in Singapore and has regional offices in Germany (Europe), Thailand (Southeast Asia) and the US (North America).
KYAN Technologies, a pioneering leader in the field of precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise. At KYAN, we have developed Optim.AI, a state-of-the-art Functional Precision Medicine test. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Our core mission is to bridge the existing gap in cancer care, and we achieve this through our unique specialization in integrating small data AI and biological experiments. Through our proprietary platform, we offer an efficient solution that transforms the identification of optimal outcomes from vast drug-dose combinations, revolutionizing the development and delivery of therapies to patients. In addition to our groundbreaking technology, KYAN is committed to conducting extensive research studies across various cancer indications, including Colorectal and Breast Cancer. These studies not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.
Nutrition Technologies (“NT”) researches, manufactures and supplies sustainable agricultural inputs (animal feed ingredients, biofertilisers and biological agents). NT uses its unique proprietary biotechnology and Black Soldier Fly Larvae (BSFL) rearing process to recycle nutrients from agricultural and food processing by-products. Their insect-based products help feed the growing agriculture and feed industries around the world. These products are suitable for application in pet food, livestock and aquatic feed, and have a range of proven functional benefits which improve yield and quality. NT's technology uses a combination of beneficial microbes and Black Soldier Fly Larvae through a zero-waste production model. Their insects are reared on fully clean and traceable agro-industrial waste streams. They have developed their own tropical business model which is not only low cost to build and operate, but also uses minimal energy and resources. This means that the company benefits from a very low cost of production, but with the same high standards as any European or North American manufacturers, and is able to pass-on those savings to the customer. The company currently ships industrial volumes of material throughout Asia, EU, US & South America, from their facilities in Malaysia. Since starting the company in 2015 in Vietnam, the company has expanded and grown and now has their main production plant, laboratory and office at multiple sites in Johor Bahru, Malaysia, with supporting labs and offices in Vietnam and Singapore. Nutrition Technologies have developed research partnerships with key institutions throughout the region to develop their products and are conducting several feed trials on key consumer species. In their latest funding round in September 2022, their venture round raised US$20m, and secured investments from Bunge, PTT, Sumitomo, INGSI, Mandala Capital, Hera Capital and Openspace Ventures.
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers in Singapore, China and Brazil. We are continuously expanding our global footprint through cooperative R&D, investment, mergers and acquisitions. Focusing on oncology and chronic diseases, Virtue Diagnostics utilizes innovative technology platforms such as clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics to expand the China market. Through local capabilities built in emerging countries, Virtue is providing completed diagnostics menu cross biochemistry, chemiluminescence and molecular technologies.
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of disease, it’s no wonder that what we do each day is more than just a job. There’s an energy across IDEXX that is contagious – where caring and committed people come together to make things better. IDEXX Laboratories, Inc. (NASDAQ: IDXX), a member of the S&P 500, is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. Headquartered in southern Maine, we conduct operations through more than 70 locations around the world and serve customers in over 175 countries. Our primary business focuses on pet health, a growing market around the world. Our products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. We also develop and manufacture diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water and milk. Please visit our website, IDEXX.com/careers, for further information and to view all of our job opportunities.
Qritive makes cancer diagnosis fast, cheap, and accurate. Qritive develops AI-powered solutions that enable histopathologic diagnosisof cancer at scale. Our clinical-decision support system for pathologists unlocks efficiency and quality gain in diagnosis, which results in better patient outcome. It includes AI Modules, an Image Management System platform (Pantheon), and a network of pathologists on-demand for services (annotations, 2nd opinion...) Our digital pathology platform has been used by several healthcare institutions in Singapore, India, Morocco, UAE, and USA, and the results have been presented at various events and journals: USCAP 2023 (deep learning on prostate biopsies), 2022 (Ki-67 on Sarcomas), and 2021 (colorectal malignancies), or Nature Scientific Report.
NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders’ personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics’ solutions are trusted by a growing number of healthcare providers, laboratories, insurers, and corporates in Asia and Europe. We have also won government grants and mandates to carry out genomic research projects from the Government of Singapore and others. These achievements reflect the company’s exceptional standards and depth of research as a scientist-led company, along with a commitment to delivering best-in-class genomic solutions. Find out more about us at www.nalagenetics.com
Vulcan Augmetics is building a distribution and data ecosystem for the $156BN biosignal sensor market. Using ML powered wireless EMG sensors with deep learning networks, our goal is to become the gateway between hardware and humanity, providing high fidelity biodata and feedback so that healthcare professionals can make better decisions for their patients, and everyday users can control their devices with their body. We have launched this technology with the worlds most affordable robotic prosthetic hand and fastest-adapting ML powered wireless sensor system
Respiree© is a digital therapeutics company providing personalized healthcare services for chronic cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. The iRIS platform by Respiree© uses data captured from remote-patient-monitors, mobile applications and medical records to longitudinally measure, track disease progression and create reports for physicians and hospitals.
About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Work Your Passion. Live Your Purpose.
